Literature DB >> 11786079

Immunoglobulin light chain amyloidosis and the kidney.

Morie A Gertz1, Martha Q Lacy, Angela Dispenzieri.   

Abstract

Immunoglobulin light chain amyloidosis and the kidney. Amyloidosis (AL) is a common cause of nephrotic syndrome in nondiabetic, nonhypertensive adults. All adult patients with nephrotic syndrome should have immunofixation of serum and urine as a screen. The finding of a monoclonal protein, particularly of lambda type, should lead to a subcutaneous fat aspirate or bone marrow biopsy to search for amyloid deposits. When the result of either test is positive, a kidney biopsy is unnecessary. The prognosis of patients who have renal amyloidosis depends on the concentration of serum creatinine at presentation and whether an echocardiographic evaluation demonstrates infiltrative cardiomyopathy. Most therapies are directed against the plasma cell dyscrasia present in all patients with AL and can include melphalan and prednisone, high-dose dexamethasone, and, most recently, peripheral blood stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11786079     DOI: 10.1046/j.1523-1755.2002.00085.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  16 in total

1.  Association between clinical characteristics and AL amyloid deposition in the kidney.

Authors:  Mitsuyo Itabashi; Takashi Takei; Misao Tsukada; Hidekazu Sugiura; Keiko Uchida; Ken Tsuchiya; Kazuho Honda; Kosaku Nitta
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

2.  [Amyloid diagnostics in rheumatic diseases].

Authors:  C Röcken; J Ernst
Journal:  Pathologe       Date:  2006-11       Impact factor: 1.011

3.  Acute liver failure due to primary amyloidosis in a nephrotic syndrome: a swiftly progressive course.

Authors:  Brigite Aguiar Cardoso; Rita Leal; Helena Sá; Mário Campos
Journal:  BMJ Case Rep       Date:  2016-03-10

4.  The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis.

Authors:  Avital Angel-Korman; Aala Jaberi; Vaishali Sanchorawala; Andrea Havasi
Journal:  Amyloid       Date:  2019-10-09       Impact factor: 7.141

Review 5.  Amyloid in the cardiovascular system: a review.

Authors:  I Kholová; H W M Niessen
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

6.  Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis.

Authors:  Julian D Gillmore; Helen J Lachmann; Dorota Rowczenio; Janet A Gilbertson; Cai-Hong Zeng; Zhi-Hong Liu; Lei-Shi Li; Ashutosh Wechalekar; Philip N Hawkins
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

7.  Current treatment in cardiac amyloidosis.

Authors:  Ivana Kholová; Josef Kautzner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-12

Review 8.  Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.

Authors:  Shveta S Motwani; Leal Herlitz; Divya Monga; Kenar D Jhaveri; Albert Q Lam
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

Review 9.  Dysproteinemias and Glomerular Disease.

Authors:  Nelson Leung; Maria E Drosou; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-07       Impact factor: 8.237

10.  [Renal lesions of paraproteinemias and fibrillary glomerulopathies].

Authors:  K Amann; C S Haas
Journal:  Pathologe       Date:  2003-10       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.